Literature DB >> 34999182

Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response.

Jesse Yu1, Qingxin Mu1, Millie Fung1, Xiaolin Xu1, Linxi Zhu1, Rodney J Y Ho2.   

Abstract

Despite advances in breast cancer treatments and related 5-year survival outcomes, metastatic breast cancer cures remain elusive. The current standard of care includes a combination of surgery, radiation therapy and drug therapy. However, even the most advanced procedures and treatments do not prevent breast cancer recurrence and metastasis. Once metastasis occurs, patient prognosis is poor. Recent elucidation of the spatiotemporal transit of metastatic cancer cells from primary tumor sites to distant sites provide an opportunity to integrate knowledge of drug disposition in our effort to enhance drug localization and exposure in cancer laden tissues . Novel technologies have been developed, but could be further refined to facilitate the distribution of drugs to target cancer cells and tissues. The purpose of this review is to highlight the challenges in metastatic breast cancer treatment and focus on novel drug combination and nanotechnology approaches to overcome the challenges. With improved definition of metastatic tissue target, directed localization and retention of multiple, pharmacologically active drugs to tissues and cells of interest may overcome the limitations in breast cancer treatment that may lead to a cure for breast cancer.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Combination therapy; Drug delivery; Metastatic breast cancer; Nanoparticles; Targeted therapy

Mesh:

Year:  2022        PMID: 34999182      PMCID: PMC9256851          DOI: 10.1016/j.pharmthera.2022.108108

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   13.400


  164 in total

Review 1.  Current status of nanomedicine in the chemotherapy of breast cancer.

Authors:  A I Fraguas-Sánchez; C Martín-Sabroso; A Fernández-Carballido; A I Torres-Suárez
Journal:  Cancer Chemother Pharmacol       Date:  2019-07-31       Impact factor: 3.333

Review 2.  Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook.

Authors:  Qingxin Mu; Jesse Yu; Lisa A McConnachie; John C Kraft; Yu Gao; Gaurav K Gulati; Rodney J Y Ho
Journal:  J Drug Target       Date:  2018-01-10       Impact factor: 5.121

Review 3.  Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.

Authors:  Kathryn J Chavez; Sireesha V Garimella; Stanley Lipkowitz
Journal:  Breast Dis       Date:  2010

4.  Lymphatic metastasis in the absence of functional intratumor lymphatics.

Authors:  Timothy P Padera; Ananth Kadambi; Emmanuelle di Tomaso; Carla Mouta Carreira; Edward B Brown; Yves Boucher; Noah C Choi; Douglas Mathisen; John Wain; Eugene J Mark; Lance L Munn; Rakesh K Jain
Journal:  Science       Date:  2002-04-25       Impact factor: 47.728

Review 5.  Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation.

Authors:  Peng Zhang; Fang Sun; Sijun Liu; Shaoyi Jiang
Journal:  J Control Release       Date:  2016-06-28       Impact factor: 9.776

Review 6.  Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.

Authors:  Grazia Arpino; Lisa Wiechmann; C Kent Osborne; Rachel Schiff
Journal:  Endocr Rev       Date:  2008-01-23       Impact factor: 19.871

7.  Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation.

Authors:  Cédric Mercier; Caroline Raynal; Laetitia Dahan; Adrien Ortiz; Alexandre Evrard; Charlotte Dupuis; Aurore Blesius; Muriel Duluc; Fleur Franceschini; Sarah Giacometti; Sébastien Salas; Gérard Milano; Roger Favre; Jean-François Seitz; Joseph Ciccolini
Journal:  Pharmacogenet Genomics       Date:  2007-10       Impact factor: 2.089

8.  Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.

Authors:  M Scaltriti; C Verma; M Guzman; J Jimenez; J L Parra; K Pedersen; D J Smith; S Landolfi; S Ramon y Cajal; J Arribas; J Baselga
Journal:  Oncogene       Date:  2008-12-08       Impact factor: 9.867

9.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

Authors:  Shanu Modi; Cristina Saura; Toshinari Yamashita; Yeon Hee Park; Sung-Bae Kim; Kenji Tamura; Fabrice Andre; Hiroji Iwata; Yoshinori Ito; Junji Tsurutani; Joohyuk Sohn; Neelima Denduluri; Christophe Perrin; Kenjiro Aogi; Eriko Tokunaga; Seock-Ah Im; Keun Seok Lee; Sara A Hurvitz; Javier Cortes; Caleb Lee; Shuquan Chen; Lin Zhang; Javad Shahidi; Antoine Yver; Ian Krop
Journal:  N Engl J Med       Date:  2019-12-11       Impact factor: 91.245

10.  In Vivo Evaluation of Dual-Targeted Nanoparticles Encapsulating Paclitaxel and Everolimus.

Authors:  Loujin Houdaihed; James Christopher Evans; Christine Allen
Journal:  Cancers (Basel)       Date:  2019-05-29       Impact factor: 6.639

View more
  4 in total

Review 1.  Nanobiotherapeutic strategies to target immune microenvironment of triple-negative breast cancer.

Authors:  Qing Chang; Liang Chang; Mo Li; Liwen Fan; Shunchao Bao; Xinyu Wang; Linlin Liu
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

2.  A minimalist and robust chemo-photothermal nanoplatform capable of augmenting autophagy-modulated immune response against breast cancer.

Authors:  Hui Ming; Bowen Li; Hailong Tian; Li Zhou; Jingwen Jiang; Tingting Zhang; Ling Qiao; Peijie Wu; Edouard C Nice; Wei Zhang; Weifeng He; Canhua Huang; Haiyuan Zhang
Journal:  Mater Today Bio       Date:  2022-05-13

Review 3.  Aggregation-induced emission photosensitizer-based photodynamic therapy in cancer: from chemical to clinical.

Authors:  Zijuan Meng; Huiying Xue; Tingting Wang; Biao Chen; Xiyuan Dong; Lili Yang; Jun Dai; Xiaoding Lou; Fan Xia
Journal:  J Nanobiotechnology       Date:  2022-07-26       Impact factor: 9.429

4.  Gastrointestinal metastasis secondary to invasive lobular carcinoma of the breast: A case report.

Authors:  Li-Xi Li; Di Zhang; Fei Ma
Journal:  World J Clin Cases       Date:  2022-09-06       Impact factor: 1.534

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.